Treatment of hereditary angioedema: A review (CME)

Transfusion

Volumn 54, Issue 11, 2014, Pages 2989-2996

  Bhardwaj, Neeti ^a   Craig, Timothy J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; BRADYKININ; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE;

ANGIONEUROTIC EDEMA; BIBLIOGRAPHIC DATABASE; CLINICAL EFFECTIVENESS; DRUG APPROVAL; EMERGENCY CARE; EUROPE; FOLLOW UP; HEALTH CARE ACCESS; HUMAN; LONG TERM CARE; LONG TERM PROPHYLAXIS; MEDLINE; OVID; PATIENT EDUCATION; PATIENT SAFETY; PEDIATRICS; PHYSICIAN; PRACTICE GUIDELINE; PROPHYLAXIS; REVIEW; SHORT COURSE THERAPY; SHORT TERM PROPHYLAXIS; TREATMENT RESPONSE; UNITED STATES; ANALOGS AND DERIVATIVES; ANGIOEDEMAS, HEREDITARY;

ANGIOEDEMAS, HEREDITARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC;

EID: 84912529488     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12674     Document Type: Review

References (49)

1. Zuraw BL,. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359: 1027-1036.
2. Donaldson VH, Evans RR,. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-esterase. Am J Med 1963; 35: 37-44.
3. Donaldson VH, Rosen FS,. Action of complement in hereditary angioneurotic edema: the role of C'1-esterase. J Clin Invest 1964; 43: 2204-2213.
4. Rosen FS, Alper CA, Pensky J, et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1971; 50: 2143-2149.
5. Austen KF, Sheffer AL,. Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. N Engl J Med 1965; 272: 649-656.
6. Davis AE 3rd,. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595-628.
7. Landerman NS,. Hereditary angioneurotic edema. I. Case reports and review of the literature. J Allergy 1962; 33: 316-329.
8. Cicardi M, Agostoni A,. Hereditary angioedema. N Engl J Med 1996; 334: 1666-1667.
9. Bygum A,. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009; 161: 1153-1158.
10. Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema: two genetic variants. Science 1965; 148: 957-958.
11. Bork K, Barnstedt SE, Koch P, et al. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-217.
12. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119: 267-274.
13. Bowen T, Cicardi M, Bork K, et al. Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. Ann Allergy Asthma Immunol 2008; 100: S30-40.
14. Bork K, Davis-Lorton M,. Overview of hereditary angioedema caused by C1-inhibitor deficiency: assessment and clinical management. Eur Ann Allergy Clin Immunol 2013; 45: 7-16.
15. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-157.
16. Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5: 182-199.
17. Parikh N, Riedl MA,. New therapeutics in C1INH deficiency: a review of recent studies and advances. Curr Allergy Asthma Rep 2011; 11: 300-308.
18. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. Ann Allergy Asthma Immunol 2012; 109: 395-402.
19. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24.
20. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-808.
21. Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks-final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-1611.
22. Bork K, Barnstedt SE,. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001; 161: 714-718.
23. Bernstein JA, Qazi M,. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability. Expert Rev Clin Immunol 2010; 6: 29-39.
24. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363: 523-531.
25. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 523-529.
26. Banta E, Horn P, Craig TJ,. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials. Allergy Asthma Proc 2011; 32: 319-324.
27. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
28. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107: 529-537.
29. Davis B, Bernstein JA,. Conestat alfa for the treatment of angioedema attacks. Ther Clin Risk Manag 2011; 7: 265-273.
30. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-827 e14.
31. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013; 110: 295-299.
32. Farrell C, Hayes S, Relan A, et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. Br J Clin Pharmacol 2013; 76: 897-907.
33. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007; 98: 383-388.
34. Nzeako UC, Frigas E, Tremaine WJ,. Hereditary angioedema: a broad review for clinicians. Arch Intern Med 2001; 161: 2417-2429.
35. Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104: 314-320.
36. Gower RG, Busse PJ, Aygoren-Pursun E, et al. Hereditary angioedema caused by c1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J 2011; 4: S9-S21.
37. Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations. Allergy Asthma Proc 2012; 33: 235-240.
38. Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009; 102: 366-372.
39. Riedl MA,. Creating a comprehensive treatment plan for hereditary angioedema. Immunol Allergy Clin North Am 2013; 33: 471-485.
40. Craig TJ,. Appraisal of danazol prophylaxis for hereditary angioedema. Allergy Asthma Proc 2008; 29: 225-231.
41. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-522.
42. Gandhi PK, Gentry WM, Bottorff MB,. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012; 32: 902-909.
43. Frank MM,. Update on preventive therapy (prophylaxis) for hereditary angioedema. Immunol Allergy Clin North Am 2013; 33: 495-503.
44. Bork K, Hardt J, Staubach-Renz P, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 58-64.
45. Macginnitie AJ,. Pediatric hereditary angioedema. Pediatr Allergy Immunol 2013 Dec 9. doi: 10.1111/pai.12168. [Epub ahead of print].
46. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010; 6: 22.
47. Zanichelli A, Magerl M, Longhurst H, et al. Hereditary angioedema with C1 inhibitor deficiency: delay in diagnosis in Europe. Allergy Asthma Clin Immunol 2013; 9: 29.
48. Lunn ML, Santos CB, Craig TJ,. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Annals Allergy Asthma Immunol 2010; 104: 211-214.
49. Farkas H,. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 2013; 14: 571-586.